118 related articles for article (PubMed ID: 12496487)
1. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1.
Becker CM; Farnebo FA; Iordanescu I; Behonick DJ; Shih MC; Dunning P; Christofferson R; Mulligan RC; Taylor GA; Kuo CJ; Zetter BR
Cancer Biol Ther; 2002; 1(5):548-53. PubMed ID: 12496487
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
4. Modeling antiangiogenesis gene therapy.
Tsai JH; Lee WM
Cancer Biol Ther; 2002; 1(5):554-5. PubMed ID: 12496488
[No Abstract] [Full Text] [Related]
5. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia.
Jacobi J; Tam BY; Wu G; Hoffman J; Cooke JP; Kuo CJ
Circulation; 2004 Oct; 110(16):2424-9. PubMed ID: 15477417
[TBL] [Abstract][Full Text] [Related]
8. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.
Szentirmai O; Baker CH; Bullain SS; Lin N; Takahashi M; Folkman J; Mulligan RC; Carter BS
J Neurosurg; 2008 May; 108(5):979-88. PubMed ID: 18447716
[TBL] [Abstract][Full Text] [Related]
9. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.
Kuhnert F; Tam BY; Sennino B; Gray JT; Yuan J; Jocson A; Nayak NR; Mulligan RC; McDonald DM; Kuo CJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10185-90. PubMed ID: 18632559
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
11. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer.
Keke F; Hongyang Z; Hui Q; Jixiao L; Jian C
Cancer Biother Radiopharm; 2004 Oct; 19(5):649-57. PubMed ID: 15650458
[TBL] [Abstract][Full Text] [Related]
12. The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.
Thobe MN; Gray JK; Gurusamy D; Paluch AM; Wagh PK; Pathrose P; Lentsch AB; Waltz SE
Oncogene; 2011 Dec; 30(50):4990-8. PubMed ID: 21625214
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Hoshida T; Sunamura M; Duda DG; Egawa S; Miyazaki S; Shineha R; Hamada H; Ohtani H; Satomi S; Matsuno S
Pancreas; 2002 Aug; 25(2):111-21. PubMed ID: 12142732
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence and Bioluminescence Imaging of Angiogenesis in Flk1-Nano-lantern Transgenic Mice.
Matsushita J; Inagaki S; Nishie T; Sakasai T; Tanaka J; Watanabe C; Mizutani KI; Miwa Y; Matsumoto K; Takara K; Naito H; Kidoya H; Takakura N; Nagai T; Takahashi S; Ema M
Sci Rep; 2017 Apr; 7():46597. PubMed ID: 28425492
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
17. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.
Burton JB; Priceman SJ; Sung JL; Brakenhielm E; An DS; Pytowski B; Alitalo K; Wu L
Cancer Res; 2008 Oct; 68(19):7828-37. PubMed ID: 18829538
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Gene therapeutic exploration: retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo.
Kou B; Li Y; Shi Y; Xia J; Wang X; Wu S
Oncol Res; 2005; 15(5):239-47. PubMed ID: 16261843
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model.
Xuan JW; Bygrave M; Valiyeva F; Moussa M; Izawa JI; Bauman GS; Klibanov A; Wang F; Greenberg NM; Fenster A
Mol Imaging; 2009; 8(4):209-20. PubMed ID: 19728975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
